Register for our free email digests:
Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Staying Diversified, Bayer Sees Opportunities In Digital Innovation
Despite its Monsanto woes, Bayer is sticking with its diversified portfolio, and is branching out into patient-facing digital health services.
Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data
Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.
NHS England Hails Biggest CAR-T Uptake In Europe
Pharma must “speak the same language” as the National Health Service for “transactable” negotiations.
UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’
Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.
ASH Preview: J&J And Legend’s CAR-T Takes Center Stage
While bluebird bio, Celgene and GSK prepare to file, it’s time to shine for another myeloma contender.